Scientific programme


Print Programme
  AUDITORIUM MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
09.30-10.45  

DERMOSCOPY COURSE PART I

 

Chairs: G. Argenziano,S. Puig, P. Soyer

 

09.30 - 09.45 How I use Dermoscopy in my practise

G. Argenziano

09.46 - 10.01 Diagnosis of melanoma

S. Puig

10.02 - 10.17 Other tumours and collisions

P. Zaballos

10.18 - 10.35 Cases with clinic-histopathology correlation

C.Carrera

Discussion: G. Argenziano, P. Soyer, S. Puig,

I. Zalaudek

International Dermoscopy Society Course
Presentation
Dermoscopy and clinical-pathologic correlation is essential in the management of skin cancer. The IDS in collaboration with the EADO and the World Melanoma Skin Cancer Centres Meeting propose a special course with medium and advanced contents that will cover the new advances in Dermoscopy and the discussion of clinical situations with pathology correlation. The course faculty is composed of relevant experts in the field and dermatopathologists who will provide a unique opportunity to enjoy a noteworthy experience.

            
10.45 - 11.00   Coffee break    
11.00-12.15  

DERMOSCOPY COURSE PART II

 

Chairs: R. Hofmann-Wellenhof, H. Kittler, A. Lallas

 

11.00 - 11.15 How I manage pink lesions

H. Kittler

11.16 - 11.31 How I manage facial lesions

R. Hofmann-Wellenhof

11.32 - 11.47 How I manage acral lesions

 A. Lallas

11.48 - 12.05 Cases with clinic-histopathology

correlation

A. Barreiro, L. Ferrandiz

Discussion: R. Hofmann-Wellenhof, H. Kittler,

A. Lallas, C. Longo, I. Zalaudek

   
13.00-14.15

SIMPOSIUM 1

Controversies & new development in melanoma

Chairs: C. Garbe - J. Malvehy

 

Will the computers replace the dermatologist?

13.00 - 13.10 Yes: J.Malvehy 

13.10 - 13.20 No: S. Puig

Is the pathology the right gold standard for melanoma?

13.25 - 13.35 Yes: L. Requena

13.35 - 13.45  No: P. Soyer

Is the new AJCC a progress?

13.50 - 14.00 Yes: J. E. Gershenwald 

14.00 - 14.10 No: J.J. Grob

 

 

 

 

   
14.15-15.30

SIMPOSIUM 2

Controversies & open questions in melanoma

Chairs: J.J. Grob - J. Thompson

 

Shall all Spitz-like tumours be excised?

14.15 - 14.25 Yes: A. Lallas

14.25 - 13.35 No:  R. Hofmann- Wellenhof

We have biomarkers for treatment decisions

14.40 - 14.50 Yes: O. Michielin

14.50 - 15.00 No: C. Blank

Do we still need surgery in advanced melanoma?

15.05 - 15.15 Yes: J. Thompson

15.15 - 15.25 No: J. Larkin

     
15.30-16.00 Coffee break - visit to the Exhibition & e-poster viewing
16.00-17.00 INDUSTRY SATELLITE SYMPOSIUM    
17.00-17.15 OPENING CEREMONY      
17.15-17.45

OPENING KEYNOTE LECTURE

Chairs: H. Pehamberger  - J. Thompson

 

Speaker: S. Aznar

     
17.45-19.00 WELCOME RECEPTION IN THE GARDEN ROOM
  AUDITORIUM MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
08.00-09.00

SYMPOSIUM 3

Epidemiology of melanoma

Chairs: S. Gandini - J. J. Grob - D. Whiteman

 

08.00 - 08.12 The worldwide burden of skin cancer

S.Gandini
 

08.15 - 08.27 What should the public be told  about prevention?

J. J. Grob
 

08.30 - 08.42 Melanoma incidence:  signs for a decline?

D. Whiteman
 

08.45 - 08.57 Melanoma: differences and trends in Europe

A. M. Forsea

BREAKOUT SESSION 1

Skin cancer guidelines: International structure & cooperation

Chairs: D. Coit - C. Garbe - J. Thompson

BREAKOUT SESSION 2
Building & EADO registry

Chairs: U. Leiter-Stöppke -

M. Weichenthal

COURSE IN DERMATO ONCOLOGY FOR NURSES

Chairs: P. Mohr

 

08.00 - 08.10 Introduction

 

08.10 - 09.30 Dermatological tumours and surgery

 

09.30 - 10.15 Chemotherapy and radiotherapy for dermatological patients

 

10.15 - 10.30 Coffee break

 

10.30 - 11.00 How to work with port systems

 

11.00 - 12.15 TKI and management of side effects in melanoma and BCC patients

 

12.15 - 13.00 Lunch break (lunch box)

 

13.00 - 14.15 Immune oncology in melanoma, SCC and Merkel cell carcinoma patients and management of side effects

 

14.15 - 15.00 Adjuvant therapy in melanoma patients

This educational activity is devoted to all nurses that can benefit from specific training in skin cancer management. This course will bring to the participants a unique opportunity to learn the particularities of the treatment of skin cancer patients including surgical procedures and local and systemic therapies. The training has the intention to be attractive to all nurse practitioners that are interested in skin cancer patients from the most experienced to the novice. The sessions will be interactive to facilitate the practical discussion of the needs of skin cancer patients between the audience and experts based in different skin cancer centres.

09.05-10.05

SYMPOSIUM 4

Actinic keratoses

Chairs: K. Peris - A. Stratigos

 

09.05 - 09.17 Epidemiology and biology of actinic keratoses

A. Stratigos

 

09.20 - 09.32 Classification and grading of actinic keratoses

G. Pellacani

 

09.35 - 09.47 Topical treatment of actinic keratoses and field cancerization 

K. Peris

 

09.50 - 10.02 New developments in the photodynamic therapy of actinic keratoses

R. M. Szeimies

SYMPOSIUM 5

Genetics of melanoma

Chairs: E. Nagore - J. Newton-Bishop - S. Puig

 

09.05 - 09.17 Genetic susceptibility to melanoma

T. Bishop

 

09.20 - 09.32 Familial melanoma

J. Newton-Bishop

 

09.35 - 09.47 Genetics and prognosis

E. Nagore

 

09.50 - 10.02 Genetics and treatment decision

S. Puig

 

WORKSHOP 1

Skin cancer prevention and screening

Chairs:  V. Del Marmol - A.M. Forsea

 

09.05 - 09.17 Skin cancer prevention - anything beyond protection?

V. Bataille

 

09.20 - 09.32 Melanoma risk factors - new insights

V. del Marmol

 

09.35 - 09.47 Skin cancer early detection - what works? What can we do better?

A.M. Forsea

 

09.50 - 10.02 Consumer-oriented apps for skin cancer prevention and detection - what can they really do?

P. Soyer

 

Skin cancer prevention & screening
Presentation
Although the new innovative therapies have recently brought a dramatic improvement to a long-time hopeless situation, the prevention and early detection of skin cancers remain crucial tools to reduce the burden of human and material costs induced by these frequent tumors.

We benefit nowadays from an explosion of new insights in the mechanisms of cutaneous oncogenesis and its risk factors, of development of the opto-spectral, non-invasive skin imaging techniques, and of evolving computer-assisted solutions for diagnosis. These are bound to shape and transform our approach to early detection and prevention in the near future.

This educational session aims to highlight the new evidence regarding major topics for skin cancer primary and secondary prevention. It aims to bring clinicians the top-new knowledge needed to guide their decisions in the every-day clinical practice for the optimal management of high-risk patients.

 

 
10.05-10.30 Coffee break - visit to the Exhibition & e-poster viewing
10.30-11.30

INDUSTRY SATELLITE SYMPOSIUM  

     
11.30-11.45

Report of BREAKOUT SESSIONS 1-2

Chairs: J. Malvehy  - U. Leiter-Stöppke -

J. Thompson

     
11.45-12.30

PLENARY LECTURES I

Chairs :

F. M. Camacho - G. Pellacani

 

11.45 - 12.05 Total body mapping, non-invasive diagnosis and AI systems in skin cancer detection

A. Halpern

 

12.07 - 12.27 How does UV induce skin cancer?

A. Virós
 

     
12.45-13.45

INDUSTRY SATELLITE LUNCH SYMPOSIUM

     
14.00-15.00  

SYMPOSIUM 6

Surgery and Neoadjuvancy therapy of melanoma

Chairs: R. Kaufman  - D. Moreno - V. Sondak

 

14.00 - 14.12 Standards and exceptions in surgery of primary melanomas

R. Kaufman

 

14.15 - 14.27 Sentinel lymph node biopsy and lymph node dissection. 

Are they still needed?

D. Moreno  

 

14.30 - 14.42 European approaches on SNB+/N+ melanoma patients

A. Testori 

 

14.45 - 14.57 Current and future role of neoadjuvant therapy

V. Sondak

SYMPOSIUM 7

New imaging diagnostic

Chairs: J. Malvehy - I. Zalaudek

 

 

14.00 - 14.12 What's new in dermoscopy of skin cancer

I. Zalaudek

 

14.15 - 14.27 Digital imaging and beyond

J. Malvehy

 

14.30 - 14.42 Confocal microscopy and OCT in skin cancer diagnosis

G. Pellacani

 

14.45 - 14.57 Electrical impedanciometry in melanoma detection

R. Hofmann- Wellenhof  

 

 

 
15.15-16.15 INDUSTRY SATELLITE SYMPOSIUM      
16.15-16.45 Coffee break - visit to he Exhibition & e-poster viewing
16.45-17.45

SYMPOSIUM 8

Adjuvant therapy in melanoma

Chairs: H. Gogas - J. Hassel

 

16.45 - 16.57 Adjuvant treatment of melanoma in the past

P. Mohr

 

17.00 - 17.12 Checkpoint Inhibition as adjuvant Treatment in melanoma

H. Gogas

 

17.15 - 17.27 BRAF/MEK Inhibition as adjuvant Treatment in melanoma

J. Hassel

 

17.30 - 17.42 Adjuvant vaccination strategies and future perspective

U. Sahin

 

SYMPOSIUM 9

Difficult to treat subtypes of melanoma

Chairs: P. Arenberger - C. Carrera -

L. Kandolf-Sekulovic

 

16.45 - 16.57 Update on treatment of lentigo maligna

C. Carrera

 

17.00 - 17.12 Update on treatment of mucosal melanoma

L. Kandolf Sekulovic

 

17.15 - 17.27 Management of melanoma in pregnancy

P. Arenberger

 

17.30 - 17.42 Management of melanoma in immunosuppressed patients

C. Lebbé

WORKSHOP 2

Dermatologic ultrasound in skin cancer patients

Chairs: F. Alfageme - P. Giavedoni

 

Dermatologic ultrasound: Practicalities and state of the art in skin oncology

P. Giavedoni

 

Multiparametric ultrasonographic assessment of non melanoma skin cancer

R. Badea

 

Ultrasonography for the follow up and prognosis of melanoma

L. Ferrándiz

 

New diagnostic approaches in dermatologic ultrasound of skin cancer: elastography, US contrasts and ex-vivo

F. Alfageme

 

Cases for the audience and discussion

Dermatologic Ultrasound in Skin Cancer Patients
Presentation
In skin cancer ultrasonography is a diagnostic tool that is integrated in the diagnostic armamentarium for the pre-surgical anatomic evaluation of the skin tumour, detection of local metastasis or recurrences of the tumour and for guided intralesional therapies among indications. With the recent introduction of new technical improvements US is evolving into an essential tool for the management of skin cancer patients in the hands of the Dermato-oncologists in collaboration with radiologists in skin cancer centres. This educational activity is devoted to professionals involved in the diagnosis and treatment of skin cancer patients from those that have no previous experience to those that are already experienced in US. This two hour training programme will include state of the art and future innovations of US in skin cancer patients with practical cases. Limited to 50 places.


FREE COMMUNICATIONS I:

Chairs: A. Barreiro -

M. Bylaitè-Bucinskiene
  AUDITORIUM MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
08:00-09:00

SYMPOSIUM 10

Treatment of advanced BCC & SCC MELANOMA

Chairs: N. Basset-Seguin - A.Stratigos - R. Vieira

 

08.00 - 08.12 Classification of advanced BCC

J. J. Grob

 

08.15 - 08.27 Update in the management of HhI in the treatment of advanced BCC

N. Basset-Seguin

 

08.30 - 08.42 Management of advanced SCC

A. Stratigos

 

08.45 - 08.57 Surgical treatment in advanced tumours

R. Vieira

SYMPOSIUM 11 

Targeted therapy

Chairs: A. Arance - G. Long - D. Schadendorf

 

08.00 - 08.12 Issues in targeted therapy in BRAF mutant melanoma: Adjuvant therapy and which BRAF/MEK combination in the metastatic setting?

G. Long

 

08.15 - 08.27 NRAS mutant melanoma: Targeted therapy, are we there yet?

D. Schadendorf

 

08.30 - 08.42 Other targets in Melanoma

R. Dummer

 

08.45 - 08.57 Targets in non-cutaneous melanoma

A. Arance

BREAKOUT SESSION 3

Data management in melanoma

Chairs: J.E. Gershenwald -

S. Puig - R. Scolyer

 

 

 

 

 

 

 

 

 

 

BREAKOUT SESSION 4

Equitance & access to treatments in Europe

Chairs: A.M. Forsea - L. Kandolf Sekulovic

 

Task force for access to innovation in skin cancer. Access to innovative medicines for metastasic melanoma and non-melanoma skin cancer in Europe and worldwide - update 2017

L. Kandolf-Sekulovic

 

ESMO initiatives for better access to medicines

J. Tabernero

 

Improving cancer patients' outcomes - a collaborative approach

A. Roediger

 

EU options for improving access to medicines

Speaker to be confirmed

 

Cancer patients' associations initiatives to influence reimbursement decision making in Europe and worldwide

B. Ryll

 

How to improve the access to innovative medicines in Europe?

Panel discussion

09.05-10.05

SYMPOSIUM 12

Management of cutaneous toxicities

Chairs: B. Dréno - C. Lebbé

 

09.05 - 09.17 BRAF +MEK (combination) inhibitors

C. Dessinioti

 

09.20 - 09.32 Immune check point inhibitor

B. Dréno

 

09.35 - 09.47 Hedgehog inhibitor

I. Zalaudek

 

09.50 - 10.02 Anti EGF

C. Lebbé

 

SYMPOSIUM 13

Melanoma biology and genetics

Chairs: V. Bataille - R. Scolyer

 

09.05 - 09.17 Melanoma genomics

R. Scolyer

 

09.20 - 09.32 Imaging and treating pre-metastasic niches in melanoma

M. Soengas

 

09.35 - 09.47 The role of UV in elderly melanoma patients

A. Viros

 

09.50 - 10.02 Microbiome and melanoma susceptibility

V. Bataille

 

10.05 - 10.17 Spitzoid tumours

J. Bauer

 

BREAKOUT SESSION 5

Running a skin cancer centre

Chairs:  G. Long - V. Sondak -

L. Thomas

 

09.05 - 09.15 What are the pros and cons of "large" cancer centres?

J. Gershemwald

 

09.18 - 09.28 Which patients and what work should be done in the Melanoma/Skin Cancer Centres?

J. Thompson

 

09.31 - 09.41 Tumour board Commission: how to manage it?

G. Long

 

Panel discussion

 

 

 

 

 

 

 

 

 

 

 

FREE

COMMUNICATIONS II

Chairs: C. Harwood - J. Oláh - A. Toll

10.05-10.30 Coffee break - visit to the Exhibition & e-poster viewing
10.30-11.30

INDUSTRY SATELLITE SYMPOSIUM 

     
11.30-11.45

Report of BREAKOUT SESSIONS 3-5

Chairs: J.E. Gershenwald - L. Kandolf-Sekulovic - L. Thomas

 

   
11.45-12.30

PLENARY  LECTURES II

Chairs: S. Puig - C. Robert

 

11.45 - 12.05 How to combine target and immunotherapy?

G. Long

 

12.07 - 12.27 Can we cure advanced metastasic melanoma patients?

A. Haushild

     
12.45-13.45

INDUSTRY SATELLITE LUNCH SYMPOSIUM  

     
14.00-15.00  

SYMPOSIUM 14

Local therapies in melanoma
Chairs: R. Andtbacka - B. Weide

 

14.00 - 14.12 Mechanisms of action of intralesional therapies

J. Becker

 

14.15 - 14.27 IL-2 and mRNA as intralesional approaches

B. Weide

 

14.30 - 14.42 Intralesional combination therapies

M. Ross

 

14.45 - 14.57 Intralesional therapies - modifiers of the tumour microenvironment

R. Andtbacka 

 

SYMPOSIUM 15

Combination therapies
Chairs: J. Larkin - C. Robert

 

14.00 - 14.12 Who should we treat with combo ipi + nivo in the clinic?

J. Larkin

 

14.15 - 14.27 ICPI + Targeted therapy combinations: we can but should we?

C. Robert

 

14.30 - 14.42 Emerging ICPI combos: clinical prospects: e.g. anti-PD1 + IDO, anti-PD1 +TVEC etc

C. Lebbé

 

14.45 - 14.57 The future: moving away from empirical and towards rational combinations

A. Ribas

SYMPOSIUM 16

Brain mets
Chairs: B. Dreno - T.K. Eigentler - F. Meier

 

14.00 - 14.12 Monoclonal antibodies in brain metastases

B. Dréno

 

14.15 - 14.27 Targeted therapy in brain metastases

T. K. Eigentler

 

14.30 - 14.42 Radiation plus targeted/immune therapy: what is known from retrospective studies?

F. Meier

 

14.45 - 14.57 Upfront radiosurgery followed by targeted or immune therapy-the Aix-Marseille University experience

J.J. Grob

15.15-16.15

INDUSTRY SATELLITE SYMPOSIUM 

     
16.15-16.45 Coffee break - visit to the Exhibition & e-poster viewing
16.45-17.45

SYMPOSIUM 17

Immunotherapy of advanced melanoma

Chairs: C. Blank - R. Dummer

C. Robert

 

16.45 - 16.57 Neo-adjuvant therapy for early stage melanoma

C. Blank

 

17.00 - 17.12 Precision immunotherapy: dream or reality

R. Dummer

 

17.15 - 17.27 Involvement of protein translation control in response to Immunotherapy

C. Robert

 

17.30 - 17.42 Rare AE during IT-

L. Heinzerling

SYMPOSIUM 18

Predictive biomarkers

Chairs: C. Höller - O. Michielin

 

16.45 - 16.57 Principles of biomarker research

R. Dummer

 

17.00 - 17.12 Predictive biomarkers for stage IV immuno

therapies

O. Michielin

 

17.15 - 17.27 Predictive biomarkers for stage IV targeted

therapies

C. Höller

 

17.30 - 17.42 Predictive biomarkers for adjuvant therapies?

P. Lorigan

WORKSHOP 3

Sentinel lymph node biopsy. Indications and surgic procedure

Chair: D. Moreno-Ramírez

 

Current indications of SLNB in dermato-oncology

R. Kaufmann

 

Mapping and navigation of he SLN

S. Vidal-Sicart

 

SLNB surgical technique

R. Vieira

 

Learning and training of the SLNB D. Moreno-Ramírez

FREE COMMUNICATIONS III

Chairs A. Arance - A. Boada

17.45-18.45

WORKSHOP 4

Evaluation of field cancerisation (AKASI method)

Chairs: T. Dirschka - G. Pellacani

 

17.45 - 18.00 Need for better methods to asses field cancerization

G. Pellacani

 

18.00 - 18.15 The AKASI method

T. Dirschka

 

18.15 - 18.45 Cases with evaluation (using the app)

A. Casari, G. Gupta, G. Micali, L. Schmitz

 

Conclusions

 

 

 

 

AUDITORIUM

MEETING ROOM 1 MEETING ROOM 2 MEETING ROOM 3
08.30-09.15

SYMPOSIUM 19
Lymphoma
Chairs: T. Estrach - E. Guenova - R. Stadler

 

08.30 - 08.42 How to recognise and treat early mycosis fungoides

E. Guenova

 

08.45 - 08.57 Targeted Therapies in cutaneous lymphomas

R. Stadler

 

09.00 - 09.12 Large scale collaborative data-base driven clinical research in CTCL and PROCLIPI update

J. Scarisbrick

     
09:15-10:00

SYMPOSIUM 20 
Rare malignant skin tumoirs

Chairs: J. Olàh - P. Saig

 

09.15 - 09.17 Other rare cutaneous neoplasms

J. Oláh 

 

09.30 - 09.42 Dermatofibrosarcoma

P. Saiag

 

09.45 - 09.57 Merkel/Kaposi sarcoma

C. Lebbé 

     
10.00-10.30 Coffee Break - Visit to Exhibition & e-poster viewing      
10.30-12.30

PLENARY LECTURES III

Chairs: C. Garbe - D. Whitaker

 

10.30 - 10.50 The emerging era of no completion lymph node dissection

D. Coit

 

10.52 - 11.12 Skin cancer in black skin

D. Whitaker

 

11.14 - 11.34 The future of immunotherapy

C. Robert

 

11.36 - 11.56 Future developments in melanoma treatment

A. Ribas

     
12.00-12.15 CLOSING CEREMONY AND AWARDS      

Secretary

SBC servicios básicos de congresos
Mont-Roig, 13 Atc 2a
08006 Barcelona
Tel. +34 933685538
Fax +34 933685829
www.sbc-congresos.com
info@sbc-congresos.com